Everything Advisors Need to Know About ARKG's Q2 Performance

The ARK Genomic Revolution ETF (ARKG) has rebounded in the past five weeks, partially offsetting negative performance and outflows experienced since the rotation to cyclicals began in February 2021.

Related Keywords

United States ,Americans ,American ,Douglas Melton ,Vertex Pharmaceuticals ,Teladoc Health ,Harvard University ,American Society Of Mass Spectrometry ,Exact Sciences ,Semma Therapeutics ,American Society ,Mass Spectrometry ,